Clinical Trial: NCT05241834
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Eli Lilly and Company |
| Information Provided By: | Eli Lilly and Company |
| Last Update Posted: | 2026-08-21 |
Study Overview
Brief Summary
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease does not get worse.
Official Title
A Phase 1 Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation Refractory to Selective RET Inhibitors
Conditions
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Intervention / Treatment
- Drug: LOXO-260
Other Study ID Numbers
- 18381
- J3T-OX-JZTA
- LOXO-NGR-21001
Start Date (Actual)
2022-03-23
Primary Completion Date (Actual)
2024-09-17
Study Completion Date (Actual)
2026-06-03
Enrollment (Actual)
70
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Eli Lilly and Company |
| Information Provided By: | Eli Lilly and Company |
| Last Update Posted: | 2026-08-21 |
Study Overview
Brief Summary
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease does not get worse.
Official Title
A Phase 1 Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation Refractory to Selective RET Inhibitors
Conditions
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Intervention / Treatment
- Drug: LOXO-260
Other Study ID Numbers
- 18381
- J3T-OX-JZTA
- LOXO-NGR-21001
Start Date (Actual)
2022-03-23
Primary Completion Date (Actual)
2024-09-17
Study Completion Date (Actual)
2026-06-03
Enrollment (Actual)
70
Study Type
Interventional
Phase
Phase 1